Figure 1From: Efficacy and safety of lopinavir/ritonavir (LPV/r) in antiretroviral-experienced subjects infected with different subtypes of HIV-1Percent of subjects infected with different subtypes that have plasma HIV-1 RNA <50 copies/mL, FDA-TLOVR analysisBack to article page